Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethinyl estradiol + norethindrone is a combination oral medication containing two synthetic hormones: ethinyl estradiol (an estrogen) and norethindrone (a progestin). It is primarily used as an oral contraceptive to prevent pregnancy by inhibiting ovulation, altering cervical mucus to impede sperm penetration, and changing the endometrial lining to prevent implantation[2][3][5]. In addition to contraception, certain formulations are approved for hormone replacement therapy (HRT) in menopausal women, where they alleviate symptoms such as hot flashes and vaginal dryness and help prevent osteoporosis by supplementing estrogen levels[4][8]. The mechanism of action involves agonism at the estrogen receptor (ethinyl estradiol) and progesterone receptor (norethindrone), mimicking endogenous female sex hormones.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethinyl estradiol + norethindrone.